Paolo Tarantino: Nectin4 amplification predicts response to enfortumab vedotin in metastatic urothelial carcinoma

Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared by Niklas Klümper, Resident in Urology and Researcher at the Institute for Experimental Oncology at the University Hospital Bonn, on X/Twitter:

“Nectin4 amplification predicts response to enfortumab vedotin in metastatic urothelial carcinoma (Objective response rate 96% amplified vs 32% not amplified). Common alteration, also found in breast and lung cancer. Very interesting when you think that HER2 amplification predicts the activity of HER2 antibody drug conjugates and some data exists also for Trop2 amplification and SG.”

Quoting Niklas Klümper’s post:

“NECTIN4 amplification predicts response to Enfortumab vedotin in metastatic urothelial carcinoma (mUC)! It occurs frequently across solid tumors (approximately 25% of mUC) leading to potential tumor-agnostic biomarker for NECTIN4-targeting therapies! Happy to share our poster K17 at GU24!”

Source: Paolo Tarantino/X and Niklas Klümper/X